Area of research
Immunology · Oncology
Research interest
Research interests include Immunotherapy and Immune Responses, CAR-T cell therapy research, Immune Cell Function and Interaction, and Cancer Immunotherapy and Biomarkers.
LIM-domain-only 4 (LMO4) enhances CD8+ T-cell stemness and tumor rejection by boosting IL-21-STAT3 signaling
Synthetic soldiers: Turning T cells into immortal warriors
Data from Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest
An engineered IL-2 partial agonist promotes CD8+ T cell stemness
Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy
Defining ‘T cell exhaustion’
T cell stemness and dysfunction in tumors are triggered by a common mechanism
Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma
The Bone Marrow Protects and Optimizes Immunological Memory during Dietary Restriction
T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy
Ribosomal Proteins Regulate MHC Class I Peptide Generation for Immunosurveillance
Mg2+ regulation of kinase signaling and immune function
Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism
Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model
Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts
Identification of essential genes for cancer immunotherapy
Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy
BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency
Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche
Constitutive LcK activity drives sensitivity differences between CD8+ memory T cell subsets
Consensus nomenclature for CD8<sup>+</sup>T cell phenotypes in cancer
Lineage relationship of CD8+ T cell subsets is revealed by progressive changes in the epigenetic landscape
The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells
Classification of current anticancer immunotherapies
Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest
T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy
Uncoupling T‐cell expansion from effector differentiation in cell‐based immunotherapy